Floatz logo

Kras Tcr-Transduced Pbl

Gastrointestinal Cancer

National Cancer Institute (NCI)Cell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

72 Active assets in the Gastrointestinal Cancer cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Brian Anderson, MD
Phase 4BB
DEXAMETHASONE
Cedars-Sinai Medical Center
Phase 4BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 2BB
Irinotecan
Amgen
Phase 2BB
Epinephrine
Cedars-Sinai Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Kras Tcr-Transduced Pbl is also rated in:

metastatic malignant neoplasmDormant
B
Indicative ·
59 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
digestive system carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →